lipoprotein(a) like 2 (pseudogene)Genealiases: APOAL · APOARGC · apo(a)rg-C
Q-omics provides the consensus-scored LPAL2 profile across patient tissues and cancer cell-line models. LPAL2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LPAL2 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, LPAL2 RNA expression shows 18,637 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, LUAD, and UVM as cancer lineages where LPAL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LPAL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LPAL2 survival associations across molecular data types. LPAL2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LPAL2 RNA expression–survival associations across cancer types. High LPAL2 expression shows unfavorable associations in ACC, KIRC, CESC and THCA, but favorable associations in LGG and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LPAL2 RNA expression.
This table summarizes LPAL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LPAL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LPAL2 shows lower tumor expression in LUAD, LUSC, BLCA, LIHC and KICH and higher tumor expression in COAD. The LUAD box plot shows higher LPAL2 RNA expression in normal versus tumor tissue (log2 FC = −1.544, t-test p < 0.001).
This table shows molecular features associated with LPAL2 in patient tissues and cancer cell lines. In patient samples, LPAL2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LPAL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and NCI60_ALL.
